Volume 25, Number 3—March 2019
CME ACTIVITY - Synopsis
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis
|Child||Year of treatment||Age, y/sex†||Weight, kg, at start of XDR TB treatment||HIV status||History of TB||Previous TB outcome||Disease site||Chest radiograph result‡||Drugs to which isolate was resistant||Drugs used at any stage during XDR TB treatment||Outcome|
|1||2008||9/F||23||–||No||No||PTB||Normal||INH, RIF, OFX, AMK, STR, EMB||INH, CAP, EMB, PZA, ETH, PAS||Lost to follow-up|
|2||2008||14/F||41||–||U, DST||Failure||PTB||Nonsevere typical TB||INH, RIF, OFX, AMK, STR||Not specified||Lost to follow-up|
|3||2007||6/M||20||+||No||No||PTB||Nonsevere typical TB||INH, RIF, CIP, AMK, STR, EMB||AMK, EMB, PZA, ETH, CIP||Died|
|4||2007||14/M||42||+||DS TB||No||PTB, EPTB||Severe not typical TB||INH, RIF, OFX, KAN, STR, EMB, ETH, PAS||CAP, MXF, LVX, ETH, CYS, PAS, AMX, CLA||Died|
|5||2001||13/F||U||U||DR TB||Failure||PTB||Nonsevere typical TB||INH, RIF, LVX, CIP, KAN, AMK, CAP, STR, EMB, PZA, ETH, PAS||CAP, STR, LVX, CIP, ETH, CYS, PAS, AMX, CLA||Died|
|6||2009||12/F||19.5||+||Both||Failure||PTB||Nonsevere typical TB||INH, RIF, OFX, KAN||CAP, MXF, EMB, PZA, ETH, CYS, PAS, AMX, CLA, CLM||Failure|
|7||2013||13/F||34||–||U||No||PTB||U||INH, RIF, MXF, OFX, KAN, AMK, CAP, STR, EMB, PZA, ETH||CAP, LVX, PZA, ETH, CYS, PAS||Died|
*Ethionamide or prothionamide was not differentially recorded; where ethionamide is stated, it implies that 1 of the 2 dugs was used. Cycloserine or terizidone was not differentially recorded; where cycloserine is stated, it implies that 1 of the 2 drugs was used. AMK, amikacin; AMX, amoxicillin; CAP, capreomycin; CIP, ciprofloxacin; CLA, clavulanic acid; CLM, clarithromycin; CYS, cycloserine; DS, drug sensitive; DR, drug resistant; DST, drug susceptibility testing; EMB, ethambutol; EPTB, extrapulmonary tuberculosis; ETH, ethionamide; INH, isoniazid; KAN, kanamycin; LVX, levofloxacin; LZD, linezolid; MXF, moxifloxacin; OFX, ofloxacin; PAS, para-aminosalicylic acid; PTB, pulmonary tuberculosis; PZA, pyrazinamide; RIF, rifampin; STR, streptomycin; TB, tuberculosis; U, unknown; XDR TB, extensively drug-resistant tuberculosis; –, negative; +, positive.
†Age at year of diagnosis.
‡By adapted Wiseman classification.
1Current affiliation: University of California, San Francisco, California, USA.
2Current affiliation: Oxford University, Oxford, UK.
3Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
4These senior authors contributed equally to this article.